General Information of Drug (ID: DMQVC3E)

Drug Name
Salvianolic acid B Drug Info
Synonyms
115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0
Indication
Disease Entry ICD 11 Status REF
Vascular dementia 6D81 Phase 2 [1]
Cross-matching ID
PubChem CID
11629084
TTD Drug ID
DMQVC3E

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor-binding protein 3 (IGFBP3) TTZHNQA IBP3_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01761227) Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia. U.S. National Institutes of Health.
2 Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020 Feb;139:98-112.